12:00 AM
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tysabri natalizumab: Postmarketing study data

Researchers at the University of Melbourne reported data from an independent analysis of 569 matched MS patients from each of the Tysabri Observational Program (TOP) and MSCOMET patient registries showing that the rate of first relapse was significantly lower for Tysabri compared to interferon beta-1a and glatiramer acetate (p<0.001). Specifically, patients receiving Tysabri had a 2.73-fold lower risk of relapse...

Read the full 290 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >